vs
iQSTEL Inc（IQST）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是iQSTEL Inc的1.5倍（$127.1M vs $84.2M），再鼎医药同比增速更快（17.1% vs -14.9%），iQSTEL Inc自由现金流更多（$-1.2M vs $-26.7M），过去两年iQSTEL Inc的营收复合增速更高（28.0% vs 20.8%）
iQSTEL Inc是一家科技控股企业，业务覆盖电信、物联网与金融科技三大核心领域，面向南北美洲市场的中小企业及零售用户提供高性价比的通信服务、智能物联网监测解决方案及数字化金融工具。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
IQST vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.5倍
$84.2M
营收增速更快
ZLAB
高出32.0%
-14.9%
自由现金流更多
IQST
多$25.5M
$-26.7M
两年增速更快
IQST
近两年复合增速
20.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $84.2M | $127.1M |
| 净利润 | $-2.7M | — |
| 毛利率 | 3.5% | 51.0% |
| 营业利润率 | -2.9% | -54.6% |
| 净利率 | -3.2% | — |
| 营收同比 | -14.9% | 17.1% |
| 净利润同比 | -44.5% | — |
| 每股收益（稀释后） | $-0.92 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IQSTZLAB
| Q4 25 | $84.2M | $127.1M | ||
| Q3 25 | $102.9M | $115.4M | ||
| Q2 25 | $72.2M | $109.1M | ||
| Q1 25 | $57.6M | $105.7M | ||
| Q4 24 | $98.9M | $108.5M | ||
| Q3 24 | $54.2M | $101.8M | ||
| Q2 24 | $78.6M | $100.1M | ||
| Q1 24 | $51.4M | $87.1M |
净利润IQSTZLAB
| Q4 25 | $-2.7M | — | ||
| Q3 25 | $-2.3M | $-36.0M | ||
| Q2 25 | $-2.3M | $-40.7M | ||
| Q1 25 | $-1.1M | $-48.4M | ||
| Q4 24 | $-1.9M | — | ||
| Q3 24 | $-773.0K | $-41.7M | ||
| Q2 24 | $-2.0M | $-80.3M | ||
| Q1 24 | $-580.2K | $-53.5M |
毛利率IQSTZLAB
| Q4 25 | 3.5% | 51.0% | ||
| Q3 25 | 2.7% | 59.5% | ||
| Q2 25 | 2.6% | 60.6% | ||
| Q1 25 | 3.4% | 63.6% | ||
| Q4 24 | 2.7% | 61.5% | ||
| Q3 24 | 3.7% | 64.1% | ||
| Q2 24 | 2.8% | 64.9% | ||
| Q1 24 | 2.7% | 61.4% |
营业利润率IQSTZLAB
| Q4 25 | -2.9% | -54.6% | ||
| Q3 25 | -0.5% | -42.3% | ||
| Q2 25 | -0.9% | -50.3% | ||
| Q1 25 | -1.0% | -53.3% | ||
| Q4 24 | -0.3% | -62.6% | ||
| Q3 24 | -0.1% | -66.6% | ||
| Q2 24 | -0.4% | -76.0% | ||
| Q1 24 | -0.4% | -80.7% |
净利率IQSTZLAB
| Q4 25 | -3.2% | — | ||
| Q3 25 | -2.3% | -31.2% | ||
| Q2 25 | -3.3% | -37.3% | ||
| Q1 25 | -2.0% | -45.8% | ||
| Q4 24 | -1.9% | — | ||
| Q3 24 | -1.4% | -40.9% | ||
| Q2 24 | -2.5% | -80.2% | ||
| Q1 24 | -1.1% | -61.4% |
每股收益（稀释后）IQSTZLAB
| Q4 25 | $-0.92 | $-0.05 | ||
| Q3 25 | $-0.68 | $-0.03 | ||
| Q2 25 | $-0.82 | $-0.04 | ||
| Q1 25 | $-0.44 | $-0.04 | ||
| Q4 24 | $-1.19 | $-0.09 | ||
| Q3 24 | $-0.40 | $-0.04 | ||
| Q2 24 | $-0.90 | $-0.08 | ||
| Q1 24 | $-0.37 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.2M | $689.6M |
| 总债务越低越好 | $4.1M | — |
| 股东权益账面价值 | $16.3M | $715.5M |
| 总资产 | $51.1M | $1.2B |
| 负债/权益比越低杠杆越低 | 0.25× | — |
8季度趋势，按日历期对齐
现金及短期投资IQSTZLAB
| Q4 25 | $2.2M | $689.6M | ||
| Q3 25 | $2.3M | $717.2M | ||
| Q2 25 | $2.0M | $732.2M | ||
| Q1 25 | $1.1M | $757.3M | ||
| Q4 24 | $2.5M | $779.7M | ||
| Q3 24 | $2.1M | $616.1M | ||
| Q2 24 | $797.2K | $630.0M | ||
| Q1 24 | $2.7M | $650.8M |
总债务IQSTZLAB
| Q4 25 | $4.1M | — | ||
| Q3 25 | $2.7M | — | ||
| Q2 25 | $4.5M | — | ||
| Q1 25 | $3.5M | — | ||
| Q4 24 | $2.5M | — | ||
| Q3 24 | $3.2M | — | ||
| Q2 24 | $2.5M | — | ||
| Q1 24 | $194.0K | — |
股东权益IQSTZLAB
| Q4 25 | $16.3M | $715.5M | ||
| Q3 25 | $17.9M | $759.9M | ||
| Q2 25 | $14.3M | $791.7M | ||
| Q1 25 | $11.6M | $810.8M | ||
| Q4 24 | $11.9M | $840.9M | ||
| Q3 24 | $8.1M | $667.7M | ||
| Q2 24 | $7.6M | $704.2M | ||
| Q1 24 | $8.4M | $762.2M |
总资产IQSTZLAB
| Q4 25 | $51.1M | $1.2B | ||
| Q3 25 | $46.9M | $1.2B | ||
| Q2 25 | $51.4M | $1.2B | ||
| Q1 25 | $42.0M | $1.2B | ||
| Q4 24 | $79.0M | $1.2B | ||
| Q3 24 | $32.4M | $985.3M | ||
| Q2 24 | $30.0M | $987.4M | ||
| Q1 24 | $22.1M | $988.4M |
负债/权益比IQSTZLAB
| Q4 25 | 0.25× | — | ||
| Q3 25 | 0.15× | — | ||
| Q2 25 | 0.31× | — | ||
| Q1 25 | 0.31× | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | 0.40× | — | ||
| Q2 24 | 0.34× | — | ||
| Q1 24 | 0.02× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.2M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $-1.2M | $-26.7M |
| 自由现金流率自由现金流/营收 | -1.5% | -21.0% |
| 资本支出强度资本支出/营收 | 0.0% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-4.0M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流IQSTZLAB
| Q4 25 | $-1.2M | $-26.0M | ||
| Q3 25 | $-953.0K | $-32.0M | ||
| Q2 25 | $257.7K | $-31.0M | ||
| Q1 25 | $-1.9M | $-61.7M | ||
| Q4 24 | $-403.7K | $-55.8M | ||
| Q3 24 | $625.0K | $-26.8M | ||
| Q2 24 | $-2.6M | $-42.2M | ||
| Q1 24 | $-536.9K | $-90.1M |
自由现金流IQSTZLAB
| Q4 25 | $-1.2M | $-26.7M | ||
| Q3 25 | $-969.2K | $-35.0M | ||
| Q2 25 | $211.7K | $-33.9M | ||
| Q1 25 | $-2.0M | $-63.2M | ||
| Q4 24 | $-421.3K | $-58.4M | ||
| Q3 24 | $594.5K | $-28.2M | ||
| Q2 24 | $-2.6M | $-42.9M | ||
| Q1 24 | $-608.5K | $-91.1M |
自由现金流率IQSTZLAB
| Q4 25 | -1.5% | -21.0% | ||
| Q3 25 | -0.9% | -30.4% | ||
| Q2 25 | 0.3% | -31.1% | ||
| Q1 25 | -3.4% | -59.9% | ||
| Q4 24 | -0.4% | -53.8% | ||
| Q3 24 | 1.1% | -27.7% | ||
| Q2 24 | -3.4% | -42.9% | ||
| Q1 24 | -1.2% | -104.5% |
资本支出强度IQSTZLAB
| Q4 25 | 0.0% | 0.5% | ||
| Q3 25 | 0.0% | 2.6% | ||
| Q2 25 | 0.1% | 2.6% | ||
| Q1 25 | 0.1% | 1.5% | ||
| Q4 24 | 0.0% | 2.4% | ||
| Q3 24 | 0.1% | 1.3% | ||
| Q2 24 | 0.0% | 0.7% | ||
| Q1 24 | 0.1% | 1.1% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IQST
| USA | $53.2M | 63% |
| Other | $29.9M | 35% |
| Switzerland | $1.1M | 1% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
